LYEL — Lyell Immunopharma, Inc.
Is LYEL overbought or oversold? Here is the current MarketMoodz read.
Lyell Immunopharma, Inc. (LYEL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $14.65. The rating moved from Neutral to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$14.65
- Last changeMoved from Neutral to Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Lyell Immunopharma is positioned as a clinical-stage cell therapy developer with a platform that could generate high upside if upcoming clinical readouts and platform validation are positive. Financial visibility is limited in the provided window, making the stock sensitive to financing needs and dilution; manufacturing and regulatory execution are key operational risks. Broader market flows favoring large-cap defensive pharma may reduce near-term investor appetite for small-cap biotech, though consolidation activity in pharma could create strategic interest. Near-term performance is likely to be driven by clinical catalysts, partnership activity, and any financing announcements.
Key factors
- Early/mid-stage cell therapy platform with potential upside tied to clinical readouts and platform validation
- Platform focus on engineered T cells that could address persistence and efficacy if clinical data are positive
- Large addressable oncology/immunotherapy market that supports meaningful commercial opportunity if programs succeed
- Sector environment showing defensive flows into large-cap pharma, which may limit short-term small-cap biotech investor appetite
- Potential M&A tailwinds from large‑cap pharma consolidation into specialty franchises could create strategic interest
- Limited near-term public financial disclosures in the provided window increases emphasis on upcoming operational and clinical milestones
Risks
- Clinical trial setbacks, negative efficacy or safety readouts that materially reduce program value
- Need for additional funding that would likely cause dilution and pressure the share price
- Manufacturing, CMC and scale-up risks inherent to cell therapy development
- Intense competition from larger, better-capitalized cell therapy and oncology developers
- Regulatory delays or unfavorable interactions with agencies that push back timelines
- Low social sentiment / limited coverage and liquidity that can amplify price volatility around news
See today's live rating, score and targets
Members see the live hourly rating for LYEL — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.